Litigation involving CTI Molecular Imaging and GE has been settled out of court. The lawsuits were initially brought by GE against CTI Molecular Imaging, its PETNET Solutions radiopharmaceuticals unit, and certain employees of CTI Molecular Imaging to
Litigation involving CTI Molecular Imaging and GE has been settled out of court. The lawsuits were initially brought by GE against CTI Molecular Imaging, its PETNET Solutions radiopharmaceuticals unit, and certain employees of CTI Molecular Imaging to prevent these former GE employees from potentially disclosing or using GE confidential information. The staff had left GE and joined CTI or PETNET before the litigation was initiated. CTI Molecular Imaging announced that the parties worked together to ensure that sufficient safeguards were in place to prevent potential disclosure of GE confidential information and further disputes. CTI Molecular Imaging will incur no charges in connection with the settlement.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.